217 related articles for article (PubMed ID: 21614454)
1. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.
Wong PC; Crain EJ; Watson CA; Schumacher WA
J Thromb Thrombolysis; 2011 Aug; 32(2):129-37. PubMed ID: 21614454
[TBL] [Abstract][Full Text] [Related]
2. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.
Wong PC; Quan ML; Watson CA; Crain EJ; Harpel MR; Rendina AR; Luettgen JM; Wexler RR; Schumacher WA; Seiffert DA
J Thromb Thrombolysis; 2015 Nov; 40(4):416-23. PubMed ID: 26249722
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.
Schumacher WA; Seiler SE; Steinbacher TE; Stewart AB; Bostwick JS; Hartl KS; Liu EC; Ogletree ML
Eur J Pharmacol; 2007 Sep; 570(1-3):167-74. PubMed ID: 17597608
[TBL] [Abstract][Full Text] [Related]
4. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
[TBL] [Abstract][Full Text] [Related]
5. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Wong PC; Crain EJ; Watson CA; Wexler RR; Lam PY; Quan ML; Knabb RM
J Thromb Thrombolysis; 2007 Aug; 24(1):43-51. PubMed ID: 17323133
[TBL] [Abstract][Full Text] [Related]
6. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Wong PC; Luettgen JM; Rendina AR; Kettner CA; Xin B; Knabb RM; Wexler R; Priestley ES
Thromb Haemost; 2010 Aug; 104(2):261-9. PubMed ID: 20589312
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis.
Wang X; Li Q; Du F; Shukla N; Nawrocki AR; Chintala M
TH Open; 2023 Apr; 7(2):e97-e104. PubMed ID: 37101592
[No Abstract] [Full Text] [Related]
8. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
Wong PC; Crain EJ; Xin B; Wexler RR; Lam PY; Pinto DJ; Luettgen JM; Knabb RM
J Thromb Haemost; 2008 May; 6(5):820-9. PubMed ID: 18315548
[TBL] [Abstract][Full Text] [Related]
9. Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.
Wong PC; Quan ML
Res Pract Thromb Haemost; 2021 May; 5(4):e12524. PubMed ID: 34095733
[TBL] [Abstract][Full Text] [Related]
10. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Wong PC; Crain EJ; Watson CA; Xin B
J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Heitmeier S; Visser M; Tersteegen A; Dietze-Torres J; Glunz J; Gerdes C; Laux V; Stampfuss J; Roehrig S
J Thromb Haemost; 2022 Jun; 20(6):1400-1411. PubMed ID: 35289054
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
[TBL] [Abstract][Full Text] [Related]
19. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.
Chi L; Mertz TE; Rogers KL; Janiczek N; Peng YW; Saganek L; Bousley RF; Juneau PL; Uprichard AC; Gallagher KP
J Thromb Thrombolysis; 2001 Feb; 11(1):19-31. PubMed ID: 11248787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]